Tactile Systems Technology, Inc. (TCMD) Earnings Call Transcript
November 2, 2026
Earnings Call Speaker Segments
Good afternoon, and thanks for being with us on today's call. Joining me from Tactile Medical's management team are Sheri Dodd, our Chief Executive Officer, and Elaine Birkemeyer, our Chief Financial Officer. Before we get started, I want to remind everyone that what we say today, including our answers to your questions, may include forward-looking statements. Those are based on management's current expectations and carry inherent risks and uncertainties. Actual results could therefore differ materially from what those statements indicate, including the risks identified in the risk factor section of our annual report on Form 10-K, along with our latest 10-Q filing, which is to be filed with the Securities and Exchange Commission. Those factors may be updated from time to time in our SEC filings, which you can find on our website. We assume no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Today's call will also reference certain financial measures that aren't calculated under generally accepted accounting principles, or GAAP. We typically call these non-GAAP financial measures. You can find reconciliations of those non-GAAP financial measures to the most comparable GAAP measures in the earnings press release posted in the investor relations section of our website. With that, I'll hand the call over to Sheri.
Thanks, Sam. Good afternoon, everyone, and welcome to our third quarter 2026 earnings call. With me today is Elaine Birkemeyer, our Chief Financial Officer. Total revenue for Q3 was $91.9 million, driven by 13% year-over-year growth in lymphedema, which represents our fifth quarter in a row of double-digit growth above the market. That consistency demonstrates how durable our leadership position is and the substantial runway created by a market that remains significantly under-penetrated. Airway clearance revenue totaled $10 million, down year-over-year as expected, due to the one-time DME inventory transition related to launching our next-generation AffloVest system. The same DME customers we mentioned in Q2 continued working through temporary excess inventory during Q3. The business's fundamental drivers remain essentially unchanged, and we continue to anticipate sequential improvement in airway clearance revenue during Q4. Throughout the portfolio, we keep pairing robust growth in our core lymphedema segment with disciplined execution. In Q3, gross margin rose 90 basis points versus the prior year to 76.7%, which helped produce adjusted EBITDA of $14.3 million; that represents the 12th quarter in a row of year-over-year gross margin gains. Notably, we have delivered this ongoing improvement even as we keep investing in our product offerings so patients and providers receive greater value. Given what we've delivered so far this year and how we see the fourth quarter shaping up, our full-year 2026 revenue guidance stays at $360 million to $366 million, while adjusted EBITDA guidance moves up to $50 million to $52 million. This view reflects our ongoing confidence in low double-digit growth across the business and our expectation that airway clearance revenue will improve sequentially in the fourth quarter. For the full year, we expect airway clearance revenue to be down mid to high single digits versus a year ago. I'll now take a closer look at our lymphedema business line, covering Q3 performance and recent progress on our three strategic priorities. Elaine will then walk through our financial results and the outlook for the rest of the year. Lymphedema is still our main business and our biggest source of growth. Our third-quarter results show we lead the market in both basic and advanced pneumatic compression devices, with revenue up 13% from a year earlier to $81.8 million. Compared with the prior quarter, lymphedema revenue rose 11%, helped by a rebound from the Medicare ordering timing disruption tied to the April start of prior authorization requirements. As we expected, the prior authorization process has settled down now that our teams and the MACs have more experience with the new requirements, and we think that timing disruption is behind us now. Medicare revenue came back to growth in Q3, up 11% year-over-year. Beyond the Medicare stabilization, the quarter's performance came from execution across several key drivers. The money we've put into our sales force and CRM tools is broadening what our commercial team can reach and accomplish. In Q3, clinic visits were up 19% compared with a year earlier, and the number of referring clinics has risen over 10% since the start of the year. What makes these results possible is better market intelligence that lets our teams spot and rank referral opportunities throughout our account base. Our clinician-focused marketing is also delivering returns we can measure. For accounts that attended certain events, orders rose 20% to 45% in the 90 days following the event compared with the 90 days prior. So far in 2026, our medical education team has trained over 13,000 clinicians who treat lymphedema patients, which is already 25% above the total for all of 2025. That widens the pool of providers able to spot patients and send them on to the right therapy. On top of that, patient access to advanced pumps has held up well since we aligned more closely with the NCD policy, and our product mix shows it. As the next stage of our go-to-market playbook, during this quarter we set up a dedicated strategic accounts team inside our larger commercial organization. That group is going to focus on deepening ties with larger health systems and IDNs, and at the same time it will create additional referral chances inside our existing high-volume regional and national accounts. Taken as a whole, this gives us confidence that we can produce sequential lymphedema growth in Q4. We're beginning to see returns on what we've invested in our operating model and order process, and those investments are lifting efficiency and service quality as patients move from referral into therapy. The difficult comparison with the prior year in the next quarter — which comes from the early benefit of our NCD alignment — will hold back year-over-year growth, though it doesn't change how confident we are in the underlying momentum of the business. Looking past the third-quarter numbers, we're making solid progress on three strategic priorities designed to keep growth in the double digits: broadening access to care, delivering value throughout the patient journey, and widening the range of treatment options. Together these priorities form a compelling growth model—one that supports current performance while strengthening the drivers behind durable lymphedema results over time. As is typical with most market development opportunities, it all starts with diagnosis. To help patients obtain clinically appropriate therapy, we first need to find them, get them diagnosed, and get them referred. Broadening access to care means assisting a greater number of patients in getting diagnosed and referred into the care pathway. A referral only kicks off the ordering process, and growth also requires converting a bigger proportion of referrals into shipments. At present, there are diagnosed lymphedema patients who never complete the paperwork and ordering steps needed to get therapy, and each one who falls out of that process is a diagnosed individual who may end up without care. Delivering value throughout the patient journey means narrowing that gap and turning a larger share of eligible referrals into shipments — that is the point where we serve the patient and where revenue comes from. Widening the range of treatment choices reinforces each stage of that path. With a broader portfolio, clinicians gain more options for their patients, more supplementary referral opportunities open up, and we can reach additional patient populations and disease stages. As these capabilities grow, we also anticipate better productivity and operating leverage that will underpin Adjusted EBITDA growth over time. To put it plainly, growth in our lymphedema business that lasts isn't just about hiring more sales reps. It comes from helping more patients get diagnosed and referred, helping more of those referrals actually reach therapy, and expanding the range of patients and therapy needs we can serve. Widening access to care through earlier diagnosis and broader patient coverage is our top priority. The opportunity in front of us is substantial. About 20 million people in the U.S. are living with undiagnosed lymphedema, and many patients who do have a diagnosis still face coverage obstacles. Our LymphaTech 3D Scanner presently provides clinicians with an FDA-cleared quantitative method for measuring limb volume and circumference, which supports identifying the disease earlier and more consistently. We’re encouraged that LymphaTech is right now being used and bringing in revenue at top academic medical centers, even before an established reimbursement pathway exists, which shows its utility in clinical practice. We hit an important regulatory milestone not long ago, securing FDA 510(k) clearance for an expanded indication for the LymphaTech 3D Scanner. LymphaTech has received clearance to provide circumference and volume readings that help evaluate lymphedema. This moves the company's clinical role beyond standalone measurement and monitoring. The expanded indication also strengthens the foundation for our broader diagnostic plan, which includes work on clinical adoption, reimbursement, and additional integrated diagnostics.
Regarding reimbursement for the LymphaTech 3D Scanner, we talked about our Category III CPT code application on the Q2 earnings call, and it's set for final review at the February 2027 meeting. A Category III code tracks usage rather than deciding coverage, but it's still a meaningful step toward broader reimbursement. Taken together, these regulatory milestones are meant to encourage wider adoption of LymphaTech—allowing lymphedema to be identified earlier and more objectively and fluid to be monitored over time—and ultimately to bring more patients into the care pathway; we're also making headway in expanding payer access for patients already diagnosed with lymphedema. Once the six-month data from our randomized controlled trial of Flexitouch therapy in head and neck cancer-related lymphedema had been published, we began noticing some movement among commercial payers, and a limited number have removed the restrictive experimental and investigational label from their policies. There is still a great deal of work to do, but these initial policy shifts demonstrate that our clinical evidence combined with payer engagement can expand coverage over time, which opens access to therapy for more eligible patients and supports additional referral opportunities. Our second priority involves generating value throughout the patient journey. We identify opportunities to enhance the experience at each stage of care, though at present we are concentrating on the stage of the journey with the greatest impact—assisting more eligible patients in successfully starting therapy. Lessening the hassle involved in initial paperwork and ordering lets us raise the rate at which referrals turn into shipments, ensuring additional patients receive the treatment their doctor ordered; that benefits patients, eases the burden on prescribing clinicians and their teams, and underpins a steadier, more productive operating structure. Ultimately, wider therapy access is a major force behind patient value as well as durable growth. This quarter, we adjusted our organizational and operating model to reinforce the way orders progress from referral through to shipment. We are likewise continuing to move our end-to-end ordering process onto a new footing via our AI-enabled order management platform along with care navigation efforts. All of these initiatives combined are meant to reduce friction, give us better visibility into how patients are progressing, and tighten execution throughout the journey from referral to shipment. Tangible results are already showing up in medical record review — just one step in the wider order process — where improvements driven by technology have reduced the typical review time by about 50%. There is still meaningful work ahead, but this early outcome demonstrates the potential to raise service levels, add capacity, and support future order growth more efficiently as we roll these capabilities out across the full end-to-end process. Building on that momentum, we are making another significant move in how our operating model evolves. As was announced today, Steve Kiewiet is coming on board at Tactile Medical as Chief Operating Officer. Steve will head up our order operations and patient services teams in this newly created position, bringing together the capabilities that serve a patient from referral all the way through shipment into a single operating organization; with this structure, decision-making across the entire journey becomes more coordinated, and we can spread process improvements further, which creates a better experience, greater capacity, and an operating model that scales more effectively. Steve brings deep and wide-ranging expertise in revenue cycle management, field-based patient educators, call center, and DME operations. The timing is right for us to add an executive-level enterprise operations leader, and we're excited to welcome him. Expanding treatment options is our third priority. A broader innovation portfolio lets us address more patient needs, support further referral opportunities, and connect with patients across a wider range of disease stages. We're pursuing opportunities that complement our core pneumatic compression therapies and expand the patient populations we can serve. Consistent with the commitment we've previously stated, October delivered a major milestone: we submitted a 510(k) application for Flexitouch Pro, a significant upgrade to our advanced pneumatic compression system. Flexitouch Pro is designed to enhance the patient and clinician experience through usability and connectivity improvements that simplify therapy administration while providing the clinical effectiveness that has kept Flexitouch the longstanding market leader. If the regulatory review goes through as expected, our goal is to bring Flexitouch Pro to market commercially during the second half of 2027. This new product is designed to strengthen our position as a leader in advanced pneumatic compression and to increase the value our core franchise delivers; in addition, we are preparing to launch MyoSleeve in the U.S. through our collaboration with ElastiMed. The next step on our roadmap is a targeted VA pilot that begins late in Q4, which will let us evaluate patient experience, clinical fit, and the right go-to-market approach before we move toward broader commercialization. MyoSleeve is not factored into our 2026 guidance, and we anticipate that its contribution will grow gradually over time. From a strategic standpoint, this gives us an opportunity to treat more patients and expand the scope of therapy needs that our portfolio is able to cover. On the whole, we continue to feel confident about the durability of our lymphedema business and about the opportunities that lie ahead in 2027 and beyond. Every one of our strategic priorities is at a different point in its development, and the impact of each will accumulate over time. Taken together, they are intended to reinforce the core drivers of our lymphedema business: additional patients being identified and referred, additional eligible patients getting therapy, and a wider array of patients and care needs that we are able to serve. That is the growth model we think can underpin durable revenue growth along with improving profitability over time. Having said that, I'll now hand things to Elaine, who will walk us through the financial results and the outlook for the full year.
Thanks, Sheri. Except where we say otherwise, every figure I cite for the third quarter is GAAP and compared with a year earlier. Total revenue for the quarter came in at $91.9 million, an increase of $6.1 million, or 7.1%, since double-digit gains in lymphedema more than made up for the decline we anticipated in airway clearance. Looking at product lines, sales of our lymphedema offerings — Flexitouch, Nimbl, and LymphaTech — rose $9.5 million, or 13.1%, reaching $81.8 million. That lymphedema growth showed up broadly across payer channels: Medicare climbed roughly 11% and commercial rose roughly 17% versus a year ago, while VA was roughly flat. Sales of AffloVest, our airway clearance product, fell $3.4 million, or 25.1%, to $10 million, in line with the DME inventory dynamics Sheri mentioned earlier. For the year to date, total revenue is up 12% at $252.8 million, with lymphedema growth of 15% leading the way. Further down the P&L, gross margin widened to 76.7% of revenue, versus 75.8% in the third quarter of 2025. That gain mostly came from lower manufacturing costs and a favorable product mix, and it matched the expectations built into our full-year outlook. Operating expenses for the third quarter rose $6.9 million, or 12.7%, to $60.9 million. The rise mainly reflected the annualization of sales force hiring done in the prior year plus ongoing investment in technology and other capabilities that support our growth. Those investments target the growth drivers Sheri laid out: generating referrals, converting more of them into shipments, and expanding our portfolio. Breaking out expenses by category, the operating expense increase consisted of a $3.2 million rise in sales and marketing, a $0.3 million rise in research and development, a $3.2 million rise in Reimbursement, general and administrative, and a $0.1 million rise in intangible asset amortization and contingent consideration. Operating income was $9.6 million, versus $11 million a year earlier. Net interest income was $0.5 million, the same as the prior year period. Income tax expense came to $3 million, compared with $3.2 million a year earlier. Net income was $7.2 million, or $0.31 per diluted share, against $8.2 million, or $0.36 per diluted share, in the third quarter of 2025. Adjusted EBITDA was $14.3 million, compared with $14.4 million a year earlier, and the adjusted EBITDA margin was 15.6% versus 16.8%. Gross margin improved 90 basis points, but higher operating expenses — including the annualization of prior year sales force hiring and continued investment in technology and operating capabilities — more than offset that gain. Year-to-date adjusted EBITDA is up approximately 35% to $29.5 million, and we still expect adjusted EBITDA growth for the full year. As our investments mature and scale over time, we anticipate operating expenses will grow more slowly than revenue, which should support operating leverage and adjusted EBITDA growth. Turning to the balance sheet, we finished the quarter with $75.1 million in cash and no outstanding borrowings, up from $69.9 million at the close of the second quarter. In the third quarter we generated $12 million in operating cash flow, which more than covered approximately $6.2 million in share repurchases. By September 30th, 2026, roughly $12.5 million was still available under the $25 million share repurchase program we have in place. Our priorities for allocating capital haven't changed; we'll keep investing in the commercial, operational, and strategic capabilities that drive organic growth, hold room for disciplined M&A, and buy back shares when valuation looks attractive to us and doing so won't hold back our strategic priorities; now let's move to our outlook. As Sheri said, we're keeping full year 2026 revenue guidance at $360 million to $366 million, which represents growth of about 9%-11% year-over-year. Better lymphedema performance is offsetting a weaker airway clearance outlook; within lymphedema, we still anticipate low double-digit growth for the full year. In the fourth quarter, we anticipate meaningful sequential growth, with year-over-year growth moderating relative to recent quarters, since we're lapping a particularly strong fourth quarter of 2025, when lymphedema grew 16% on the initial benefit of NCD alignment. In airway clearance, full year revenue is now expected to decline in the mid to high single digits, versus our earlier expectation of approximately flat. DME customers are taking longer than we initially expected to work through existing inventory as they transition to the next generation AffloVest, so we now assume a more gradual normalization of ordering. That reflects ordering timing rather than any change in patient demand or market leadership; we expect sequential improvement in the fourth quarter, with revenue still below the prior year, consistent with our full year outlook. Our total revenue range mainly reflects the timing of lymphedema referrals converting to shipments in the fourth quarter, our seasonally largest quarter. For modeling purposes, here's what we expect for the full year: GAAP gross margin of approximately 76.5%, GAAP operating expense growth of 10%-12%, net interest income of approximately $2.4 million, an effective tax rate of approximately 28%, and fully diluted weighted average shares outstanding of approximately 23 million. We're raising full year 2026 EBITDA guidance to $50 million-$52 million, representing growth of approximately 12%-16% compared with $44.8 million in 2025. Our adjusted EBITDA expectation includes these adjustments: stock-based compensation expense of approximately $8.6 million, depreciation and amortization expense of approximately $7.3 million, executive transition costs of approximately $1.3 million, acquisition-related and integration costs of approximately $1.3 million, and litigation-related costs of approximately $1 million. With that, I'll hand the call back to Sheri for some closing remarks. Sheri?
Thanks, Elaine. In closing, this quarter showed again how strong and durable our core lymphedema business is. We posted yet another period of double-digit lymphedema growth, saw gross margins expand, and produced solid cash flow, all while putting money into the capabilities that can underpin our next stage of growth. The opportunity ahead goes far past the patients we serve right now. If we help more patients get diagnosed and referred, turn more of those referrals into shipments, and widen the range of patients and therapy needs we can address, we think we can keep growing the market we serve and raising the value we create across the patient journey. At the same time, we stay focused on turning that growth into greater operating leverage as time goes on. Our revenue guidance mirrors our year-to-date performance and what we expect for the rest of the year, and our adjusted EBITDA guidance shows ongoing financial discipline as we invest to support long-term growth. We believe Tactile is well-positioned to deliver durable growth, expand operating leverage, and create long-term value for our shareholders. Last, I want to thank our Tactile Medical employees for their continued commitment to our patients, our clinical customers, and one another. With that, operator, we'll now open the call for questions.
Good evening, Sheri and Elaine. Elaine, congratulations. The profitability — you've got the company in really strong fighting shape. I just wanted to say that. If I could ask a little about 2027. I know it's early, and we won't get guidance, but first, as we think through any puts and takes, especially with the airway clearance business normalizing, I wanted to hear your thoughts on that. Second, to ask it a different way, is there any reason the lymphedema market would change or slow down, or your position and growth would be affected in any way? Thinking about what Flexitouch Pro brings, plus ElastiMed's contribution arriving in 2027, and possibly gains from LymphaTech — it feels like the business should speed up somewhat, especially in lymphedema. Thanks. I realize that's a big ask.
Hey there, Ryan. We're over here smiling, and we appreciate you mentioning the profitability side. A great deal of effort has gone into that area, and we're grateful you noticed. Let me take your final point first, the lymphedema business. There's no cause we can identify for a slowdown. In fact, greater awareness in the market—combined with the diagnostic entering the picture and policies that, we hope, keep favoring the right patient getting the right pump at the right time—works in our favor as a byproduct. From where we sit, given how we operate and our field presence, we don't believe this disease area, this category, or our business within it is one that would experience a slowdown. So our confidence is high when it comes to lymphedema as a core growth driver for the business, and we see the market as extremely favorable in that area. Regarding your 2027 question, we won't be providing any particular guidance for that year. Still, where the lymphedema business is concerned, we have strong confidence in its durable growth, which is reflected in the double-digit expansion posted across the last five quarters in a row — including 13% during this quarter by itself. Now regarding AffloVest, as mentioned, Q4 inventory timing will differ somewhat; we expect sequential growth from Q3 into Q4, though it will be somewhat more tempered than what we described in Q2, since we've gained additional insight into current developments; even so, we think that business will return to being a solid business, and we'll be able to compete with the offering we have, our next-generation AffloVest product, which remains the sole untethered vest; it is still the lightest vest. It's a connected vest, and it keeps delivering strong value for patients. We won’t provide any guidance for 2027, but I hope that gives you a sense of our thinking.
That's quite useful. Regarding Flexitouch Pro, are there any factors we should keep in mind, whether on pricing or margin, as you bring it to market? I know you mentioned some benefits, perhaps in qualitative terms, but any quantitative details would be helpful. Thank you. Thanks for taking the questions.
Yeah, absolutely. Flexitouch Pro will be classified as an E0652, so reimbursement will remain at its current level, and we expect that to hold for next year, which typically rises at the same COLA rate. There won't be any upside or anything different from what the reimbursement actually is from a code perspective. Internally, gross margins will be in the same neighborhood as our existing products.
Thank you.
Of the current Flexitouch portfolio.
Hi, Kyle here, filling in for Adam. Appreciate you taking the question. I'll try my luck once more with a 2027 question. I realize you aren't giving guidance right now, but looking at it from a P&L perspective, 2025 was a year of investment. In 2026, plenty of investments were made too, and yet you still managed to deliver decent EBITDA growth in both of those years. I'm just curious — maybe at a high level, qualitatively — how are you viewing that for next year? Should we be expecting some continued leverage while you're still putting money into growth? Any color on that would help. Thank you.
Yes. Appreciate the question; so, we've made a commitment to operating leverage, that's our commitment, and we will keep delivering that into next year. This year, naturally, we had some annualization of the sales rep head count, and we keep investing in our business, both when it comes to the transformational platform for our order operations, and those investments will carry on into 2028. But we do expect ongoing leverage, and that's our objective — to grow the top line and the bottom line alike. On the revenue side, and as I mentioned in my comments with Ryan, nothing suggests anything is heading downward, that would be dragging things, or that the market is turning less attractive. The reality is that a large proportion of patients are underserved, and there's no automatic button that suddenly lets a whole bolus of patients get diagnosed, even with the 3D Scanner in our portfolio. A lot has to happen before these patients get diagnosed. They still need the documentation. They still need to see their physician. So, we believe a healthy market exists there, but I also want to temper expectations somewhat — there isn't simply a sudden hockey stick that occurs, just because we'll now have the Flexitouch Pro and the 3D Scanner. It takes time, it's chipping away, but we're in the best position to show durable, sustainable growth in a way that returns value to shareholders.
Good, that's useful.
Ryan, does that address what you were asking?
Yes, it did. That was great. Maybe just quickly, as a follow-up, congrats on the head and neck payer progress. I just wanted to ask if you're willing to put a number on how many wins you've had in removing some of that restrictive language. Also, is there anything you could quantify about when we might start to see some gradual revenue contribution from that population, or just how you expect that to play out with those payer wins?
Yes. In line with what we said before, I wish I had a different story here, but the way commercial policies get overturned and changed has to be grounded in evidence and in being kind of top of mind for the payers. We won't put a number on it or name the individual payers, but certain policies did shift, moving from E&I to covered. That tells us the evidence is landing, that payers will revise their rules, and from there it's simply steady blocking and tackling all the way through to make that change happen. That takes time as well, and we'll factor what we think that pace will be into our 2027 revenue, though it won't be a hockey stick either. The encouraging part is that a growing number of patients will be able to obtain the sole therapy on the market—compression pump treatment—for the head and neck region after they have come through head and neck cancer. That makes it a meaningful technological step forward for a significant patient group, and we keep pushing very hard to get those policies revised.
That's useful. Thank you.
Hi, Sheri. Hi, Elaine. I appreciate the question. First, on AffloVest, could you speak a bit about — you mentioned that rebuilding inventory has been taking somewhat longer than you'd anticipated. Just talk a bit about the visibility you actually have into AffloVest sell-through, and perhaps why rebuilding inventory is taking somewhat longer, and your confidence that we're at the trough here on inventory.
Yeah. Thanks, Brandon. So in Q3, AffloVest came in as expected, and we issued our guidance at a time based on what we saw. As we've moved into Q4, we're seeing that pace of working through the inventory being somewhat slower than we forecasted when we last spoke with you. That's reflected in our current earnings, as we've shown here. What's behind it is, again, no new DMEs have suddenly come forward saying they have inventory. It's the same DMEs we identified in Q2. Depending on where that inventory sits, sometimes it's at individual branches, and sometimes it's central, but it can vary. While we don't have real-time visibility into every location, we do know that because this is so concentrated among a few of our customers, when their timing is off, it actually can affect our quarter; so that's why we're being prudent, and we're providing the guidance specifically on Afflo, and we're calling it as we see it, which is a slight slowdown. What we do know is that there's no change in underlying patient demand, therapy effectiveness, or competition. So those things remain true. It's just this pace. In our indirect business model, those aren't things I can impact directly. What we can do, again, is having great therapy, continue to train, continue to help the DMEs and support the work they're doing. But this pace really isn't something I can directly control, and we're calling it as we see it right now.
All right, thank you. Moving to the lymphedema side, you provided a metric that we don't typically receive, namely that referring clinics rose 10% year-to-date. I'm curious whether you might discuss how that figure has tended to trend historically. Is it a solid leading indicator for you folks when you think about growth ahead? Which kinds of accounts are newly joining the referral network? Do they differ from what they've traditionally been? Any further thoughts on that would help. I found it a worthwhile and interesting metric reflecting the success you're achieving with referrals. I'd just like more detail on how it's evolving and how it could affect the business. Thanks.
Yeah. This likely isn't a metric we'll refresh each time, but as we considered what to share, we felt it made sense to add a bit more quantification regarding how rep productivity truly looks. So there are two elements, correct? We now have additional feet on the street, and we discussed rep productivity getting a boost from the CRM tool. On top of that, we layer in market data that genuinely assists the rep in pinpointing where patients receive diagnoses, and whether those patients are at clinics they already visit, or perhaps at clinics beyond the present call point. That improved market insight truly helps our teams spot and rank referral opportunities. So quite simply, additional feet on the street plus superior tools. Although those insights aren't real-time—they lag three to six months—the data remains solid. That's the reason we're witnessing this very pleasing rise in clinic visits on a year-over-year basis. Then, in addition, I provided certain metrics on our marketing programs alone, in fact displaying the 90-day pre and the 90-day post, and what that genuinely does to support order growth. When we examine metrics such as these for our sales and marketing investments, then share a handful of them with you, the hope is that you're seeing the value of the investments we made in 2025 and where our dollars keep going in 2026.
Good evening, and thanks for taking my questions. To start, on airway clearance and the DMEs, presumably some of them have worked through inventory issues. Could you say anything about what you're seeing from those that don't have the inventory situation?
Sure. Looking at our small handful that have inventory issues, they're burning through it. As for those without excess inventory, who went in and are currently selling Gen 6, what we're hearing is really strong feedback on the product from both clinicians and patients. Things seem to be progressing well, and we keep assisting—just as we do for those holding excess inventory—helping DMEs spot bronchiectasis patients who haven't started treatment yet; all of that is proceeding as it has been. One caution I'd raise, however: despite solid Gen 6 uptake, among the small handful still working through surplus inventory, our Q4 forecast accounts for both the strength seen where inventory isn't a problem and the drag where it is. Ben, frankly speaking, the drop-off from working through that surplus stock is simply too large for the results in our other DMEs to offset. Those areas are doing fine, yet they aren't able to make up for the pullback among the ones carrying the extra inventory.
All right, that's useful context. So if I peek ahead to 2027, is there anything you can share about what the field sales force might look like as we move into or come out of next year?
You know what? We're really excited to essentially be putting our playbook into action. When I say excited about that, it's one thing to say you've got a playbook, and another thing entirely to actually use it. We're on, I believe, part six of our go-to-market playbook, and its foundation is that as territories grow larger, we'll split them. Then, when we split that territory, we'll install both what we call a territory account manager and that product specialist. So each time you split, you add two more people. As we watch territory performance, we'll be looking at splitting, and a few of those that may be underperforming could see some consolidation. But nothing dramatic is going to happen here. We'll simply run it the way we said we were going to run it. The one difference, and I mention this in the script, is that we did stand up a strategic accounts function. That strategic accounts function, I think, is a natural evolution of any field commercial organization when national accounts exist, those accounts that are starting to become kind of high volume. How do you have a differentiated offering and more of a key account manager who helps support both the programs and the relationships? So, standing that up just this past quarter, we won't see any revenue tied to that in Q4, but we definitely would expect strong revenue performance going into 2027, in line with the realities that I mentioned before. You want to have that connectivity to the strategic account, but it doesn't suddenly, all at once, open up thousands and thousands and thousands of referrals that start coming through in a fast clip; but it's just a maturing of our organization, and strategic accounts is a really good first step for us.
All right, that's clear. And my final question concerns the LymphaTech clearance — congratulations on securing it. My understanding is that right now you're generating revenue from it through a SaaS approach. Should that Category I code eventually come through, are you planning to remain with SaaS, or might this instead work as a click fee, or do you have any views you'd be willing to share regarding how it ends up being monetized?
That entire business model is still under review on our end. We're glad that at present the 3D Scanner has a few sizable academic centers that pay for it under a SaaS arrangement. CPT 3, the coding, begins only as a tracking code, and it has to be built up gradually. So we're at an early point in developing that reimbursement pathway. After that, we will be taking — and are in fact taking — and more can be disclosed next year about what the actual business model will look like; so obviously we're happy to have received approval for the expanded indication. That represents step one. The category three code becomes step two, and after that comes actually reaching full commercialization gear, which we expect to see later in 2029.
That's somewhat further ahead, but I appreciate your input on that. Nice work on the quarter, and thanks for the questions.
Thank you. Appreciate it, Ben.
Thanks, Chris. I want to express my appreciation to all of you for the thoughtful questions. We're glad to have once again delivered against our core business — that 13% growth in lymphedema — and to have done what we said we would do. We handled the AffloVest shortfall, so to speak, through that strength in lymphedema, and we're really pleased that we can maintain our guide for the year and raise our pull-up on the EBITDA guide as we finish out the year. So, thank you, and we look forward to having the one-on-one conversations; for everyone else, we'll see you next quarter.
Thank you, everyone, for joining us. That brings today's call to an end. Please go ahead and hang up whenever you're ready, and we hope the rest of your day goes well.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tactile Systems Technology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Tactile Systems Technology, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.